188 related articles for article (PubMed ID: 17144239)
1. Study of ovarian cancer management.
Gaughan E; Javaid T; Cooley S; Byrne P; Gaughan G
Ir Med J; 2006 Oct; 99(9):279-80. PubMed ID: 17144239
[TBL] [Abstract][Full Text] [Related]
2. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma.
Ben-Baruch G; Sivan E; Moran O; Rizel S; Menczer J; Seidman DS
Gynecol Oncol; 1996 Mar; 60(3):393-6. PubMed ID: 8774644
[TBL] [Abstract][Full Text] [Related]
3. Presenting symptoms of epithelial ovarian cancer.
Lataifeh I; Marsden DE; Robertson G; Gebski V; Hacker NF
Aust N Z J Obstet Gynaecol; 2005 Jun; 45(3):211-4. PubMed ID: 15904446
[TBL] [Abstract][Full Text] [Related]
4. Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage.
Partheen K; Levan K; Osterberg L; Helou K; Horvath G
Genes Chromosomes Cancer; 2004 Aug; 40(4):342-8. PubMed ID: 15188458
[TBL] [Abstract][Full Text] [Related]
5. Stage III papillary serous cystadenocarcinoma of the ovary in a 15-year-old female.
Moen MD; Cliby WA; Wilson TO
Gynecol Oncol; 1994 May; 53(2):274-6. PubMed ID: 8188094
[TBL] [Abstract][Full Text] [Related]
6. [Results of cytoreductive surgery for advanced and recurrent ovarian neoplasms and papillary serous carcinomas of the peritoneum].
Ivanov S; Ivanov S
Akush Ginekol (Sofiia); 2004; 43(5):36-8. PubMed ID: 15518283
[TBL] [Abstract][Full Text] [Related]
7. The role of abdominal-pelvic radiotherapy in the management of uterine papillary serous carcinoma.
Kwon J; Ackerman I; Franssen E
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1439-45. PubMed ID: 15275730
[TBL] [Abstract][Full Text] [Related]
8. Stage I ovarian carcinoma: different clinical pathologic patterns.
Deligdisch L; Pénault-Llorca F; Schlosshauer P; Altchek A; Peiretti M; Nezhat F
Fertil Steril; 2007 Oct; 88(4):906-10. PubMed ID: 17920404
[TBL] [Abstract][Full Text] [Related]
9. Papillary serous carcinoma of the peritoneum coexisting with or after endometrial carcinoma.
Altaras MM; Bernheim J; Zehavi T; Drucker L; Uziel O; Fishman A
Gynecol Oncol; 2002 Feb; 84(2):245-51. PubMed ID: 11812082
[TBL] [Abstract][Full Text] [Related]
10. Results after conservative treatment of serous borderline tumors of the ovary with a micropapillary pattern.
Laurent I; Uzan C; Gouy S; Pautier P; Duvillard P; Morice P
Ann Surg Oncol; 2008 Dec; 15(12):3561-6. PubMed ID: 18820973
[TBL] [Abstract][Full Text] [Related]
11. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer.
Everett EN; French AE; Stone RL; Pastore LM; Jazaeri AA; Andersen WA; Taylor PT
Am J Obstet Gynecol; 2006 Aug; 195(2):568-74; discussion 574-6. PubMed ID: 16890558
[TBL] [Abstract][Full Text] [Related]
12. Surgical staging, treatment, and follow-up of borderline tumors in different hospital categories: a prospective nationwide survey in Finland.
Kumpulainen S; Kuoppala T; Leminen A; Komulainen M; Puistola U; Sankila R; Mäkinen J; Grénman S
Acta Obstet Gynecol Scand; 2007; 86(5):610-4. PubMed ID: 17464592
[TBL] [Abstract][Full Text] [Related]
13. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of clinical characteristics of extraovarian peritoneal serous papillary carcinoma with papillary serous ovarian carcinoma].
Peng YZ; Shen K; Wu M; Huang HF; Pan LY; Yang JX; Lang JH
Zhonghua Fu Chan Ke Za Zhi; 2005 Apr; 40(4):243-5. PubMed ID: 15924670
[TBL] [Abstract][Full Text] [Related]
15. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P
Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
[TBL] [Abstract][Full Text] [Related]
16. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays.
Berchuck A; Iversen ES; Lancaster JM; Dressman HK; West M; Nevins JR; Marks JR
Am J Obstet Gynecol; 2004 Apr; 190(4):910-25. PubMed ID: 15118612
[TBL] [Abstract][Full Text] [Related]
17. Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.
Storey DJ; Rush R; Stewart M; Rye T; Al-Nafussi A; Williams AR; Smyth JF; Gabra H
Cancer; 2008 May; 112(10):2211-20. PubMed ID: 18344211
[TBL] [Abstract][Full Text] [Related]
18. Outcome of ovarian cancer patients who underwent incomplete surgical staging.
Panprom P; Lertkhachonsuk R
J Med Assoc Thai; 2008 Sep; 91(9):1323-30. PubMed ID: 18843859
[TBL] [Abstract][Full Text] [Related]
19. Ovarian serous papillary cystadenocarcinoma stage IIIC in a 19-year-old.
Laframboise S; Dubuc-Lissoir J
Gynecol Oncol; 1997 Feb; 64(2):279-81. PubMed ID: 9038277
[TBL] [Abstract][Full Text] [Related]
20. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma.
Thomas MB; Mariani A; Cliby WA; Keeney GL; Podratz KC; Dowdy SC
Gynecol Oncol; 2007 Nov; 107(2):190-3. PubMed ID: 17825394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
